Dualitas Therapeutics
PrivateLast Round
Series A
Sep 16, 2025
Est. Valuation
$87M
Total Funding Raised
$65M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Dualitas Therapeutics is a biotechnology company that develops next-generation bispecific antibody therapies for immunology and inflammation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dualitas Therapeutics Comparables
Compare Dualitas Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cantai Therapeutics | 82% | |
| InduPro | 81% | |
| Mabylon AG | 76% |
Dualitas Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 16, 2025 |
Key People
Founding team and executive leadership
Dualitas Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Seed, Series A |
| Chugai Venture Fund | Series A |
| Versant Ventures | Series A |
| Alexandria Venture Investments | Series A |
| Qiming | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 435% MoM, reaching 2K.
- Jun 23, 2026
Monthly visitors grew 413% MoM, reaching 1K.
Recent news
Latest coverage and updates
- is_developingSep 18, 2026
Dualitas Therapeutics, Inc. is developing novel bispecific antibodies for I&I diseases on Sep 18th '26.
- signs_new_clientSep 17, 2026
Dualitas Therapeutics, Inc. signs new client Roche.
- receives_financingSep 17, 2026
Dualitas Therapeutics, Inc. received financing of $36.5M on Sep 17th '26.
Dualitas Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Dualitas Therapeutics's valuation, stock price, and market status.
Is Dualitas Therapeutics a public or private company?
Dualitas Therapeutics is a private company.
What is the current stock price of Dualitas Therapeutics?
Dualitas Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Dualitas Therapeutics worth (valuation)?
Valuation information for Dualitas Therapeutics is not publicly available.
Can I buy Dualitas Therapeutics stock?
Dualitas Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Dualitas Therapeutics's last funding round?
Dualitas Therapeutics's most recent funding round was Series A on September 16, 2025.
Who are the main investors in Dualitas Therapeutics?
Key investors in Dualitas Therapeutics include Versant Ventures.
Will Dualitas Therapeutics IPO soon?
No public IPO plans have been announced for Dualitas Therapeutics.
How can I track Dualitas Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Dualitas Therapeutics's secondary market activity and sign up for updates.